Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01028781 · ClinicalTrials.gov registry record · Phase 1
Open Label of Thalidomide in Treatment of Women With Chronic Pelvic Pain Associated With Endometriosis
A Phase 1 study, sponsored by University of North Carolina, Chapel Hill.
- Terminated
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
NCT01028781 is a Phase 1 study that was terminated before completion, run by University of North Carolina, Chapel Hill. The registered enrollment target is 9 participants.
The verdict
NCT01028781, a Phase 1 study, was terminated before completion, sponsored by University of North Carolina, Chapel Hill.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
Patients will undergo a standard history and physical examination detailing objective clinical exam findings performed by one of the co-investigators. The research coordinator will obtain baseline values for intensity of pain, quality of life, and coping strategies. Baseline serum levels inflammatory markers will then be measured. Over the course of 12 weeks Thalidomide will be titrated as tolerated to achieve a minimum of a 30% reduction of pain on VAS from week 2.
Interventions
- DRUG Thalidomide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2006-10 |
| Est. Completion | 2009-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01028781
The ClinicalTrials.gov registry entry for NCT01028781 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of North Carolina, Chapel Hill, which has 1,109 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Thalidomide is the first listed.
NCT01028781 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01028781 about?
NCT01028781 is a clinical study titled "Open Label of Thalidomide in Treatment of Women With Chronic Pelvic Pain Associated With Endometriosis". Patients will undergo a standard history and physical examination detailing objective clinical exam findings performed by one of the co-investigators. The research coordinator will obtain baseline values for intensity of pain, quality of life, and coping strategies. Baseline serum levels inflammator...
What is the current status of trial NCT01028781?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2006-10. Estimated completion is 2009-08.
What interventions are being tested in trial NCT01028781?
The interventions under investigation include: Thalidomide (DRUG).
Who is sponsoring clinical trial NCT01028781?
This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.